Related Experiment Video
Updated: Apr 20, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Dysfunctional high-density lipoproteins in children with chronic kidney disease
Ryohei Kaseda1, Kathy Jabs1, Tracy E Hunley1
1Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
Insights
Childhood chronic kidney disease (CKD) impairs high-density lipoprotein (HDL) function, affecting inflammation and endothelial responses. This study reveals altered HDL properties in pediatric CKD patients, impacting vascular health.
Area of Science:
- Pediatric Nephrology
- Cardiovascular Research
- Lipid Metabolism
Background:
- High-density lipoproteins (HDLs) possess vasoprotective functions.
- The impact of childhood chronic kidney disease (CKD) on HDL functionality is not well understood.
Purpose of the Study:
- To investigate whether CKD in children impairs the vasoprotective functions of HDLs.
- To assess the effects of HDLs from children with CKD on macrophage and endothelial cell responses.
Main Methods:
- HDLs were isolated from children with end-stage renal disease on dialysis (ESRD), moderate CKD, and healthy controls.
- Macrophage inflammatory markers, chemotaxis, and cholesterol efflux were analyzed.
- Endothelial cell adhesion molecules, proliferation, apoptosis, and necrosis were evaluated.
Main Results:
- HDLs from children with CKD and ESRD heightened cytokine response and disrupted macrophage chemotaxis compared to controls.
- HDLs from CKD/ESRD groups were less effective in reducing endothelial adhesion molecule expression and protecting against monocyte adhesion.
- While equally protective against apoptosis, HDLs from CKD/ESRD groups showed reduced capacity as cholesterol acceptors and did not promote endothelial proliferation.
Conclusions:
- Childhood CKD significantly impairs specific HDL functions.
- CKD alters HDL's role in controlling inflammation and endothelial responses, even without long-standing risk factors.
Objectives:
Our aim was to determine if chronic kidney disease (CKD) occurring in childhood impairs the normally vasoprotective functions of high-density lipoproteins (HDLs).
Materials And Methods:
HDLs were isolated from children with end-stage renal disease on dialysis (ESRD), children with moderate CKD and controls with normal kidney function. Macrophage response to HDLs was studied as expression of inflammatory markers (MCP-1, TNF-α, IL-1β) and chemotaxis. Human umbilical vein endothelial cells were used for expression of adhesion molecules (ICAM-1, VCAM-1, E-selectin) and adhesion. Cellular proliferation, apoptosis, and necrosis of endothelial cells were measured by MTS/PMS reagent-based assay, flow cytometry, and ELISA. Cholesterol efflux was assessed by gas chromatographic measurements of cholesterol in macrophages exposed to HDLs.
Results:
Compared with HDL(Control), HDL(CKD) and HDL(ESRD) heightened the cytokine response and disrupted macrophage chemotaxis. HDL(Control) reduced endothelial expression of ICAM-1, VCAM-1, E-selectin, whereas HDL(CKD) and HDL(ESRD) were less effective and showed reduced capacity to protect endothelial cells against monocyte adhesion. Compared with a dramatically enhanced endothelial proliferation following injurious stimulus by HDL(Control), neither HDL(CKD) nor HDL(ESRD) caused proliferative effects. HDLs of all three groups were equally protective against apoptosis assessed by flow cytometry and cleaved caspase-3 activity. Compared to HDL(Control), HDL(CKD) and HDL(ESRD) trended toward reduced capacity as cholesterol acceptors.
Conclusion:
CKD in children impairs HDL function. Even in the absence of long-standing and concomitant risk factors, CKD alters specific HDL functions linked to control of inflammation and endothelial responses.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Chronic Kidney Disease IV: Nursing Management

